FDA Re-Inspection Clears Akorn’s Facility in Illinois for Production

Drug GMP Report
A A
FDA investigators have cleared Akorn’s facility in Illinois for production, following a re-inspection that confirmed the company corrected several GMP deficiencies.

To View This Article:

Login

Subscribe To Drug GMP Report